N IP 00001
Alternative Names: N-IP-00001Latest Information Update: 10 Dec 2024
Price :
$50 *
At a glance
- Originator NeoTrials
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Unspecified
Most Recent Events
- 29 Oct 2024 Neotrials plans a phase I trial (In volunteers) in Australia (Inhalation) (NCT06662019)
- 28 Oct 2024 Preclinical trials in Unspecified in Australia (Inhalation) before October 2024 (NCT06662019)